Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

1,057 total articles

PVH at $61: When a Global Brand Owner Trades Like a Melting Ice Cube

PVH at $61: When a Global Brand Owner Trades Like a Melting Ice Cube

PVH has slid back toward its 52-week lows even as profitability metrics and cash generation remain solid on paper. At roughly $61, the stock trades at single-digit earnings and mid-single-digit EV/EBITDA with a sub-0.6x price-to-book multiple. This setup looks less like “broken business” and more like “broken sentiment,” creating a mid-term trade o…

Expedia’s Pullback Looks More Like a Reset Than a Reversal

Expedia’s Pullback Looks More Like a Reset Than a Reversal

Expedia Group has rallied hard into early 2026, then backed off as momentum cooled. Even with that rally, valuation still looks defensible when you anchor on free cash flow, EV/EBITDA, and a business that is showing tangible operating leverage. Technically, the stock is working off overbought conditions with RSI in the low 40s and price below short…

Nano Labs: A Small-Cap Crypto-Reserve Pivot With A Tactically Bullish Tape

Nano Labs: A Small-Cap Crypto-Reserve Pivot With A Tactically Bullish Tape

Nano Labs is a micro-cap semiconductor design company that has increasingly been framed by the market as a crypto-reserve and Web3 optionality story, anchored around BNB accumulation. With the stock back above key short- and intermediate-term moving averages and MACD in bullish momentum, the trade skews long as long as price holds above the recent …

Cabaletta Bio: Following the Insider Footsteps Into a High-Short Setup

Cabaletta Bio: Following the Insider Footsteps Into a High-Short Setup

Cabaletta Bio (CABA) is a clinical-stage autoimmune cell therapy name with improving momentum, elevated short interest (about 11 days to cover), and several upcoming clinical and regulatory milestones. With the stock reclaiming key moving averages and still far below its 52-week high, this is a tactically interesting long trade. The setup is not ab…

Apple Looks Priced Right, But The Tech Narrative Feels Stuck

Apple Looks Priced Right, But The Tech Narrative Feels Stuck

Apple is trading near $261 with improving momentum and a valuation that looks easier to defend than it did a few weeks ago, even though the product technology narrative (especially around AI-led form factors) still feels more speculative than confirmed. This sets up a pragmatic mid-term long trade: buy strength above key moving averages, target a m…

Credo Technology: A High-Conviction Dip Setup in AI Connectivity

Credo Technology: A High-Conviction Dip Setup in AI Connectivity

Credo Technology is a pure-play on high-speed connectivity inside AI data centers. After a sharp drawdown from its 52-week high, CRDO is now trading with a depressed RSI and below key moving averages, setting up a defined-risk dip-buy trade. The bull case leans on real operating momentum (including triple-digit revenue growth cited in recent covera…

Intel’s 2026 Setup: A Pullback That Can Reset the Next Leg Higher

Intel’s 2026 Setup: A Pullback That Can Reset the Next Leg Higher

Intel has sprinted off its 2025 lows and is now pulling back from a fresh 52-week high near $54.60. The tape looks like a classic digestion phase: RSI is neutral (~47.8), price is sitting near the 20-day average, and MACD is still barely positive. My trade idea is to go long on this reset, looking for a move back toward the mid-to-upper $50s as 202…

Nebius: Capacity Is the Story, Not the Candle

Nebius: Capacity Is the Story, Not the Candle

Nebius (NBIS) is acting like a classic AI infrastructure momentum name: headline-driven volatility on top of a simpler underlying engine - demand for GPU capacity. With shares back near a key support zone around the mid-$90s and short interest elevated, the risk-reward favors a defined long trade as long as $91 support holds. This is not a ‘sleep w…

Pfizer at $26 Looks Like a Setup, Not a Surrender

Pfizer at $26 Looks Like a Setup, Not a Surrender

Pfizer is trading around $25.88 with improving momentum and a 6.65% dividend yield. Even as the market debates big-picture healthcare policy shifts, PFE’s valuation looks compressed versus its cash generation profile and the stock is building a base just under the 52-week high. This trade idea targets a measured breakout with defined risk, leaning …

Alphabet at $4T: Great Company, Stretched Setup

Alphabet at $4T: Great Company, Stretched Setup

Alphabet has climbed back near its highs with a ~$4.02T market cap and a ~$335 share price, but the valuation is getting harder to justify if free cash flow doesn’t re-accelerate. At ~32x earnings and a rich ~55x free cash flow multiple, the market is paying up for an AI-driven upside scenario at the same time momentum is rolling over (bearish MACD…